Home » Topics » Regulatory » EMA

EMA
RSS

Nintedanib obtains positive opinion in European Union for the treatment of IPF

Nov. 24, 2014

Cosentyx receives positive CHMP opinion for first-line treatment of psoriasis

Nov. 24, 2014

E.U. orphan drug designation given to Xeris' soluble glucagon

Nov. 13, 2014

EMA accepts Oleogel-S10 MAA for review

Nov. 5, 2014

European COMP gives positive opinion on orphan drug designation for IVA-337 in systemic sclerosis

Nov. 4, 2014

EMA releases third and final module on influenza vaccine guidance for public consultation

Nov. 3, 2014

EMA publishes revised guideline on biosimilars

Nov. 3, 2014

T-cell immunotherapy ATIR receives EMA orphan status for acute myeloid leukemia

Oct. 31, 2014

EMA committee recommends approval for Rixubis in patients with hemophilia B

Oct. 28, 2014

CHMP recommends approval of Duavive

Oct. 28, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...